Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
China Pharma Holdings ( (CPHI) ) has provided an update.
On February 5, 2026, Hainan Helpson Medical & Biotechnology Co., Ltd., a wholly owned subsidiary of China Pharma Holdings, Inc., agreed to acquire full ownership of an invention patent covering a Topiroxostat nanoemulsion and its preparation method from inventor Xiaoyun Chen. Under the Technology Transfer Agreement, the transferor or a designated third party will also provide supporting technical services, including product R&D, preparation of registration materials, and regulatory application work.
As consideration, China Pharma will pay $8.82 million in the form of its common stock valued at $0.70 per share, resulting in the planned issuance of 12,600,000 restricted shares to the non‑U.S. transferor in an offshore transaction. The closing of this share‑based technology acquisition was expected to be completed by February 20, 2026, signaling a strategic move by China Pharma to strengthen its intellectual property base and pipeline through a non‑cash, equity‑funded deal.
The most recent analyst rating on (CPHI) stock is a Sell with a $0.79 price target. To see the full list of analyst forecasts on China Pharma Holdings stock, see the CPHI Stock Forecast page.
Spark’s Take on CPHI Stock
According to Spark, TipRanks’ AI Analyst, CPHI is a Neutral.
The score is held down primarily by very weak financial performance (large losses, extremely negative ROE, and negative cash flows) and bearish technicals (below major moving averages with negative MACD). Corporate actions provide some strategic positives (pipeline patents and capital-structure flexibility), but dilution/reverse-split risk and loss-making fundamentals keep the overall score low.
To see Spark’s full report on CPHI stock, click here.
More about China Pharma Holdings
China Pharma Holdings, Inc., through its wholly owned subsidiary Hainan Helpson Medical & Biotechnology Co., Ltd., operates in the pharmaceutical and biotechnology industry. The company focuses on developing and producing medical products, and this transaction centers on expanding its portfolio with a patented formulation technology for a Topiroxostat nanoemulsion, a specialized drug delivery innovation.
Average Trading Volume: 54,992
Technical Sentiment Signal: Sell
Current Market Cap: $3.48M
Learn more about CPHI stock on TipRanks’ Stock Analysis page.